ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griese, M.
Right arrow Articles by Hartl, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griese, M.
Right arrow Articles by Hartl, D.
Eur Respir J 2008; 32:783-795
Copyright ©ERS Journals Ltd 2008

Inhibition of airway proteases in cystic fibrosis lung disease

M. Griese1, M. Kappler1, A. Gaggar2 and D. Hartl1

1 Children’s Hospital of Ludwig Maximilians University, Munich, Germany, 2 University of Alabama at Birmingham, Birmingham, AL, USA.

CORRESPONDENCE: M. Griese, Ludwig Maximilians University, Children’s Hospital, Lindwurmstr. 4, D-80337 Munich, Germany. Fax: 49 8951607872. E-mail: matthias.griese{at}med.uni-muenchen.de

Keywords: Antiproteases, antitrypsin, cystic fibrosis, elastase, lung disease, proteases

Received: November 5, 2007
Accepted March 31, 2008

Progressive lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients.

CF lung disease is characterised by endobronchial inflammation sustained by bacterial infections and an ongoing accumulation of airway neutrophils. Activated or necrotic neutrophils liberate proteases that cause damage to structural, cellular and soluble components of the pulmonary microenvironment.

Among various proteases released by airway cells, elastase is considered to play the major role in CF lung disease. Based on this concept, several therapeutic approaches have been developed to inhibit free elastolytic activity, including small synthetic chemical compounds, semi-synthetic inhibitors and natural inhibitors of free elastase.

The present review summarises and discusses the pathophysiological rationales, methodological requirements and clinical implications of inhibition of airway proteases in cystic fibrosis lung disease.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
P. D. Sly, S. Brennan, C. Gangell, N. de Klerk, C. Murray, L. Mott, S. M. Stick, P. J. Robinson, C. F. Robertson, S. C. Ranganathan, et al.
Lung Disease at Diagnosis in Infants with Cystic Fibrosis Detected by Newborn Screening
Am. J. Respir. Crit. Care Med., July 15, 2009; 180(2): 146 - 152.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the European Respiratory Society.